Theranostics in nuclear medicine practice

Anna Yordanova(Active Medicine (United Kingdom)), Elisabeth Eppard(Institute of Radiotherapy and Nuclear Medicine), Stefan Kürpig(Institute of Radiotherapy and Nuclear Medicine), Ralph A. Bundschuh(Active Medicine (United Kingdom)), Stefan Schönberger(Society of Paediatric Oncology and Haematology), Maria A. González-Carmona, Georg Feldmann(University Hospital Bonn), Hojjat Ahmadzadehfar(Active Medicine (United Kingdom)), Markus Essler(Active Medicine (United Kingdom))
OncoTargets and Therapy
October 1, 2017
Cited by 232Open Access
Full Text

Abstract

The importance of personalized medicine has been growing, mainly due to a more urgent need to avoid unnecessary and expensive treatments. In nuclear medicine, the theranostic approach is an established tool for specific molecular targeting, both for diagnostics and therapy. The visualization of potential targets can help predict if a patient will benefit from a particular treatment. Thanks to the quick development of radiopharmaceuticals and diagnostic techniques, the use of theranostic agents has been continually increasing. In this article, important milestones of nuclear therapies and diagnostics in the context of theranostics are highlighted. It begins with a well-known radioiodine therapy in patients with thyroid cancer and then progresses through various approaches for the treatment of advanced cancer with targeted therapies. The aim of this review was to provide a summary of background knowledge and current applications, and to identify the advantages of targeted therapies and imaging in nuclear medicine practices.


Related Papers

No related papers found

Powered by citation graph analysis